HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 09, September 2019 – Healthy Ageing — How Science is chipping in       » Officials in China make progress in development of new drugs       » The Science of Healthy Ageing       » Thailand Medtech landscape - Customer to Innovator       » China-Thailand Joint Research Institute on Medicine Launched in Bangkok      
NEWS CRUNCH
Imugene commences first patient dosing of HER-Vaxx Phase 1b/2 Gastric Cancer Study
All eight clinical sites in Asia are actively recruiting. The study is being conducted in Asian countries where there are high rates of gastric cancer and where patients have difficulty accessing expensive antibody treatments such as Herceptin and Perjeta.

Imugene Limited, an immuno-oncology company has announced it has commenced its first patient dosing of the Phase 1b/2 clinical study of its HER-Vaxx immunotherapy in gastric cancer. Patients are currently being enrolled at eight key cancer hospital sites in Asia, including Hong Kong, Thailand and Taiwan.

Imugene is testing a therapeutic anti-cancer vaccine called HER-Vaxx, in HER2+ gastric cancer patients.

Principal investigator, Univ. Professor Dr. Dr.h.c. Christoph Zielinski and Chairman, Clinical Division of Oncology and Department of Medicine at the Medical University Vienna stated, "Our team is excited to be part of this important study and the search for effective new treatments for gastric cancer as there are limited options for patients."

Imugene Chief Executive Officer, Leslie Chong said, "The successful start of this study represents an important development milestone for our business and medical professionals seeking new ways to treat patients with gastric cancer."

HER-Vaxx is designed to produce a strong antibody response against a growth signal receptor protein called HER2 which is found on the cell surface in gastric cancers.

The study is being conducted in Asian countries where there are high rates of gastric cancer and where patients have difficulty accessing expensive antibody treatments such as Herceptin and Perjeta.

Based on preclinical data recently published[1], Imugene believes HER-Vaxx will stimulate a rapid and strong immune response against cancerous cells.

The Phase 1b lead-in trial is testing three different doses of the HER-Vaxx vaccine with up to 18 patients (three groups up to six patients) in combination with chemotherapy across eight trial sites.

The key endpoints are to identify the optimal dose of HER-Vaxx for the Phase II part of the study, and confirm safety. Researchers will monitor the patient's immune responses to the vaccine.

The current study will be followed by a randomised open label Phase II study with around 68 patients with metastatic gastric cancer overexpressing HER2. The study will be randomised into two arms of either HER-Vaxx plus standard-of-care (chemotherapy) or standard-of-care alone. The endpoints of this randomised trial will be safety, immune response, progression-free survival and overall survival.

[1] Joshua Tobias, Joanna Jasinska, Karin Baier, Michael Kundi, Nicholas Ede, Christoph Zielinski, Ursula Wiedermann, Enhanced and long term humoral and cellular immunogenicity of a Her-2/neu hybrid-CRM197 peptide vaccine, using the Th1-driving adjuvant Montanide, BMC cancer, 2017, 17, 118 click here to view

Source: Imugene
NEWS CRUNCH  
news New computational fluid dynamics solution for modeling aerosol mixtures in biomedical and environmental research
news Medial Fair Thailand opened on 11th September 2019 with a focus on future-proofing Thailand's healthcare industry to meet the challenges and opportunities of the next decade
news Biofuel Producers and Users to Convene in Singapore for Global Biofuels Summit
news Philip Morris International opens artificial intelligence competition to develop improved strategies for medical diagnosis
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy